[CLSTR]
< Back to situations

Monitor this situation.

[SITUATION] · [QUIET] · [BUSINESS]

2 clusters · 6 sources · 10 days · First seen · Last updated

Indian pharmaceutical industry growth and innovation shift

Overview

The Indian pharmaceutical industry is experiencing significant market expansion alongside a strategic push toward research and development. In September 2026, the market recorded its strongest monthly growth in three years, with a year-on-year increase of 17.1 per cent. This growth was driven by demand in chronic disease management, vitamins, minerals, and nutritionals.

Parallel to this commercial growth, leaders from major firms including Sun Pharma, Biocon, and Glenmark Pharmaceuticals are advocating for a structural shift in the industry. Executives are calling for a transition “from volume to value,” moving away from a reliance on generic medicines toward high-value innovation. To achieve this, industry leaders emphasized the need for sustained R&D investment, regulatory reforms, and the development of a stronger ecosystem to compete globally in new drug development.

Entities

Kiran Mazumdar-Shaw · Biocon · Dilip Shanghvi · Indian Pharmaceutical Market · Sun Pharma

Timeline

  1. [BUSINESS] 4 sources
    India pharmaceutical market sees strongest growth in three years

    India's pharmaceutical market saw its strongest monthly growth in three years in September 2026, while industry leaders urge a shift from generic volume to high-value drug innovation.

  2. [BUSINESS] 2 sources
    Indian pharma leaders urge shift from generics to innovation

    Indian pharmaceutical leaders urge a transition from generic drug manufacturing to innovation-led growth through increased R&D investment and regulatory reform.

Sources

bhaskarlive.in · businessnewsthisweek.com · medicaldialogues.in · morungexpress.com · myrepublica.nagariknetwork.com · sanmarg.in